🔍

Chemiesynth (Vapi) Ltd (539230)

📊 BSE: 539230 🏢 Specialty Chemicals 📢 Latest filing: 13 Aug 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Chemiesynth (Vapi)'s revenue was ₹4.2 Cr (+5.7% year on year, -23.7% on the previous quarter), and net profit ₹-0.6 Cr (a bigger loss than a year earlier); the operating margin was 0.9%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹4.2	+5.7%	-23.7%
Operating profit	₹0.0	-78.4%	-96.3%
Net profit	₹-0.6	loss widened	to loss
EPS (₹)	-1.90	loss widened	to loss
Operating margin	0.9%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Chemiesynth (Vapi) Ltd Corrects AGM Book Closure and Benpose Dates

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Aug 2026, 04:41 PM

Chemiesynth (Vapi) Ltd has issued a corrigendum to rectify clerical errors in its board meeting outcome dated August 12, 2026. The share transfer book closure for the 40th Annual General Meeting (AGM) is now scheduled from September 24, 2026, to September 30, 2026. Additionally, the Benpose date for dispatching AGM notices has been moved from August 29 to August 28, 2026. These changes are administrative and do not impact the company's financials or operations.

Corrected Share Transfer Book Closure period: 24/09/2026 to 30/09/2026
Revised Benpose Date for AGM notice: 28/08/2026
Rectification of typographical error in the original filing dated 12/08/2026
Purpose of the closure is for the 40th Annual General Meeting

💡 Investors should update their records with the corrected dates for the upcoming AGM; no further action is required as this is a procedural correction.

₹15 Cr Fundraise via Preference Shares and 460% Increase in Authorized Capital

🟢 POSITIVE ⭐ 9/10

FUNDRAISE 📅 12 Aug 2026, 04:11 PM

Chemiesynth (Vapi) Ltd has approved a significant fundraise of ₹15 crore through the issuance of 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis to promoters or identified persons. This infusion is highly material, representing approximately 62.5% of the company's current market capitalization of ₹24 crore and 150% of its net worth. To accommodate this, the board is seeking shareholder approval to increase the authorized share capital from ₹3.25 crore to ₹18.25 crore. The preference shares carry a 5% cumulative dividend and have a 7-year tenure, providing long-term quasi-equity support to the loss-making entity.

Proposed issuance of ₹15 crore in 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) to Promoter Group/Identified Persons.
Authorized share capital to be increased from ₹3.25 crore to ₹18.25 crore, a 461% increase.
Fundraise amount of ₹15 crore represents approximately 71% of the company's TTM revenue of ₹21 crore.
NCRPS tenure is fixed at 7 years with a 5% cumulative dividend, payable preferentially over equity shares.
Both Call and Put options are available after 2 years from the date of allotment.

💡 Monitor the upcoming AGM on September 30, 2026, for shareholder approval of the capital increase and the specific utilization plan for the ₹15 crore proceeds, particularly whether it will be used for debt reduction or capacity expansion.

₹15 Cr Fundraise via Preference Shares and Increase in Authorized Capital

🟢 POSITIVE ⭐ 9/10

FUNDRAISE 📅 12 Aug 2026, 04:10 PM

Chemiesynth (Vapi) Ltd has approved a major fundraise of ₹15 crore through the issuance of 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis to promoters or identified persons. This infusion is highly material, representing approximately 62.5% of the company's current market capitalization (₹24 Cr) and 150% of its net worth (₹10 Cr). To facilitate this, the board has proposed increasing the authorized share capital from ₹3.25 Cr to ₹18.25 Cr. The preference shares carry a 7-year tenure with a 5% cumulative dividend, providing long-term capital to the specialty chemicals firm.

Proposed fundraise of ₹15 crore via 5% cumulative preference shares on a private placement basis.
Authorized share capital to be increased by ₹15 crore, from ₹3.25 Cr to ₹18.25 Cr.
The fundraise amount of ₹15 Cr is equivalent to approximately 71% of the company's TTM revenue of ₹21 Cr.
Preference shares have a tenure of 7 years with a Put/Call option exercisable after 2 years.
40th Annual General Meeting (AGM) scheduled for September 30, 2026, to approve these proposals.

💡 Monitor the specific utilization of the ₹15 crore proceeds, particularly whether it is used to reduce the existing ₹16 crore debt or for capacity expansion. Investors should also review the detailed Q1 FY27 financial results once fully published to assess operational recovery.

₹15 Cr Fundraise via Preference Shares and Increase in Authorized Capital

🟢 POSITIVE ⭐ 9/10

FUNDRAISE 📅 12 Aug 2026, 04:03 PM

Chemiesynth (Vapi) Ltd has approved a significant fundraise of up to ₹15 crore through the issuance of 5% Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis. This capital infusion is substantial, representing approximately 150% of the company's current net worth (₹10 Cr) and 62.5% of its market capitalization (₹24 Cr). To facilitate this, the board has proposed increasing the authorized share capital from ₹3.25 crore to ₹18.25 crore. The funds are expected to be sourced from the promoter group or identified persons, with a 7-year tenure and a 5% cumulative dividend.

Proposed issuance of ₹15 crore in 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS)
Authorized share capital to be increased by 461% from ₹3.25 crore to ₹18.25 crore
Fundraise amount of ₹15 crore is approximately 1.5x the company's current net worth of ₹10 crore
NCRPS carries a 5% cumulative dividend and a 7-year tenure with put/call options after 2 years
40th Annual General Meeting (AGM) scheduled for September 30, 2026, to seek shareholder approval

💡 Investors should monitor the upcoming Q1 FY27 results and the AGM proceedings for clarity on how the ₹15 crore will be utilized—specifically whether it will be used for debt reduction (current debt is ₹16 Cr) or business expansion.

Chemiesynth (Vapi) to consider Q1 results and Preference Share issuance on August 12

🔵 WATCH ⭐ 6/10

BOARD_MEETING 📅 06 Aug 2026, 12:37 PM

Chemiesynth (Vapi) Ltd has scheduled a board meeting for August 12, 2026, to approve its Q1 FY27 unaudited financial results. Crucially, the board will also consider a proposal to issue Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) via private placement and an increase in Authorized Share Capital. This follows a fiscal year (FY26) where the company reported a net loss of Rs 0.99 Cr and carries a high Debt-to-Equity ratio of 1.60. Investors should also note the agenda includes approving Related Party Transactions with group companies and promoters.

Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
Proposal to issue Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis.
Plan to increase Authorized Share Capital and amend the Memorandum of Association (MOA).
Approval of Related Party Transactions with Group Companies and Promoters scheduled for discussion.
Trading window remains closed from July 01, 2026, until 48 hours after the results declaration.

💡 Monitor the specific terms of the NCRPS issuance, including the coupon rate and redemption period, as well as the volume of Related Party Transactions relative to the company's Rs 21 Cr TTM revenue.

View All 539230 Announcements on Live Market Tracking →